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Abstract
Background and Purpose: Vascular calcification, recapitulating bone formation, has a profound impact on plaque stability.
The aim of the present study was to determine the influence of bone-like vascular calcification (named osteoid
metaplasia =OM) and of osteoprotegerin on plaque stability.
Methods: Tissue from carotid endarterectomies were analysed for the presence of calcification and signs of vulnerability
according to AHA grading system. Osteoprotegerin (OPG), pericytes and endothelial cells were sought using immuno-
histochemistry. Symptoms and preoperative imaging findings (CT-scan, MRI and Doppler-scan) were analyzed. Human
pericytes were cultured to evaluate their ability to secrete OPG and to influence mineralization in the plaque.
Results: Seventy-three carotid plaques (49 asymptomatic and 24 symptomatic) were harvested. A significantly higher
presence of OM (18.4% vs 0%, p,0.01), OPG (10.2% of ROI vs 3.4% of ROI, p,0.05) and pericytes (19% of ROI vs 3.8% of ROI,
p,0.05) were noted in asymptomatic compared to symptomatic plaques. Consistently, circulating OPG levels were higher
in the plasma of asymptomatic patients (3.2 ng/mL vs 2.5 ng/mL, p = 0.05). In vitro, human vascular pericytes secreted
considerable amounts of OPG and underwent osteoblastic differentiation. Pericytes also inhibited the osteoclastic
differentiation of CD14+ cells through their secretion of OPG.
Conclusions: OPG (intraplaque an plasmatic) and OM are associated with carotid plaque stability. Pericytes may be involved
in the secretion of intraplaque OPG and in the formation of OM.
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Introduction
Arterial calcification (AC) is independently associated with
increased cardiovascular morbidity and mortality [1], and its
development in atheromatous lesions impacts deeply on plaque
stability [2]. AC is now reconized as a highly-regulated process
which recapitulates bone tissue formation and homeostasis [3–5].
Observation of bone-tissue, named osteoid metaplasia (OM) and
even of bone marrow in vessels has been reported many years ago
[6]. Osteoblast-like cells have been identified in atheromatous
lesions and while the exact nature of these cells remains to be fully
determined, several lines of evidence support that pericytes are
serious candidates [7–9]. Also, giant multinucleated cells positive
for tartrate-resistant acid phosphatase (TRAP) have been identi-
fied in atherosclerosis lesions [10]. They most likely originate from
intraplaque macrophages, which have the ability to differentiate
into osteoclast-like cells in the presence of RANK-Ligand [11].
Comprehension of the mechanisms underlying the formation of
mineralized tissue within carotid atherosclerosis lesions is of high
importance since calcification greatly influences the plaque
stability and the consecutive risk of stroke [2,3,12]. At the
molecular level, the OPG- RANK-RANKL triad, fundamental in
bone homeostasis is also present in atheroma lesions [13], further
suggesting that atheromatous calcification micro-environment
reproduce landmark characteristics of bone tissue. Osteoprote-
gerin has been positively associated with the severity of coronary
artery disease and cardiovascular mortality in humans [14–16],
but also with the severity of peripheral artery disease [17],
symptomatic carotid lesions [18], and vulnerable carotid plaques
[19]. However, its exact clinical relevance regarding the develop-
ment of OM and plaque stability in carotid lesions remains to be
elucidated. Importantly, if well-defined characteristics of vulner-
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able carotid plaques are available (intraplaque hemorrage, thin
fibrous cap, large necrotic core) [20],their use in the context of
preoperative patient risk-assessment is limited and clinically
relevant markers of carotid plaque vulnerability are awaited with
much anticipation.
The aim of the present study was to investigate the influence of
OM on carotid plaque stability and to test the hypothesis that
pericytes and OPG are determinant in this process.
Materials and Methods
Patients, biological samples and imaging data
From February 2008 to June 2010, atheromatous plaques were
harvested from 73 patients undergoing carotid endarterectomy in
our center. Patients presenting with non-atherosclerotic peripheral
arterial disease, thrombosis and/or restenosis were excluded.
Detailed demographic and clinical characteristics recorded were:
age, sex, treatments, cardiovascular risk factors, medical history,
and serum biochemistry analyses. All participating patients to the
study gave a written informed consent. The clinical research
protocol was approved by our institutional medical ethics
committee (Nantes University Hospital Ethics Committee).
Doppler-ultrasound (Doppler-us) examination associated with
either angio-MRI or angio CT-scan were carried out to assess
the characteristics of the lesions and intra-cerebral collaterality, as
well as potential cerebral lesions. The results of these examinations
were thoroughly reviewed by one of the author who was blinded to
the symptomatic or asymptomatic status of corresponding patient.
Based on the imaging findings, the calcic burden of the plaques
was determined and plaques were categorized as highly calcified,
moderately calcified, mildly calcified or non-calcified. Carotid
plaques were considered as symptomatic when carotid stenosis $
50–70% was associated with the onset of ipsilateral transient
ischemic attack or stroke or retinal ischemia and in the absence of
other cause following extensive pre-operative workup. In this case,
surgery associated with best medical treatment (antiplatelet agent,
statin therapy and correction of cardiovascular risk factors) was
indicated [21,22]. Surgery consisted of endarterectomy and was
performed within 2–4 weeks of the ischaemic event [23,24].
Indication for carotid endarterectomy for asymptomatic carotid
lesions was stenosis $60–70% according to NASCET criteria and
with acceptable life expectancy [22–25].
Blood samples were collected in EDTA tubes 24 h prior to
surgery, and plasma was isolated by centrifugation, aliquoted and
stored at 280uC until use.
OPG measurement
OPG levels were measured in plasma and cell culture
supernatants by a validated enzyme immunoassay using commer-
cially available matched antibodies (DY805 ELISA kit, R&D
Systems, Minneapolis, Minn., USA). Osteoblastic pericyte-condi-
tioned medium was obtained as follow: pericytes were cultured for
16 to 18 days in an osteoblastic-inducing medium. Then, cells
were washed and a new medium, containing only 1% FCS, was
used. After 48 hours the supernatant was harvested, centrifuged,
aliquoted and stored at 280uC. Experiments were repeated three
times in duplicate.
Histological and immunological analyses
Carotid plaques were removed by endarterectomy at the
bifurcation from within the lumen as a single specimen. The
atherosclerotic plaques were immersed in physiological serum,
transferred to ice, and fixed in 10% formalin overnight, decalcified
in Sakura TDE 30 fluid for 24 h, and embedded in paraffin.
Adjacent sections (5 mm thick, 20 sections per patient) were
stained with (i) hematoxylin eosin (HE), (ii) masson trichrome, or
incubated with monoclonal antibodies directed against (iii) CD31
(dilution 1/20, M823, Dako), (iv) NG2 (frozen sections, dilution 1/
25, MAB2585, R&D Systems, Minneapolis, MN), (v) CD146
(dilution 1/200, AB75769, Abcam, Paris, France), (vi) smooth
muscle actin (dilution 1/75, MAB1420, R&D Systems), and (vii)
osteoprotegerin (dilution 1/25, AF805, R&D Systems). Plaques
were analyzed for the presence of calcification which were
categorized in sheetlike calcifications, nodular calcifications, clear
center calcifications and osteoid metaplasia, as previously
described [26]. The latter type consisted in typical mature bone
with lamellar structure and in some cases bone-marrow. The
sections were also examined separately by two authors, who were
blinded to the status of the plaque, for the presence of signs of
vulnerability according to Stary’s classification [20]: plaques with
thick fibrous or fibrocalcic content covering central necrotic core
were considered as stable (types IV, Vb and c) as opposed to
unstable plaques that presented with thin or ruptured fibrous cap,
large necrotic core (type IV and Va) or hemorrhage or ulceration
(type VI).
Imaging of the sections was obtained with the NanoZoomer
device (Hamamatsu Photonics, Hamamatsu, Japan) and staining
quantification was carried out using Image J software (Image J,
NIH, Bethesda, MD). Results were expressed as a percentage of
region of interest (ROI).
Cell culture and differentiation assays
Reagents were purchased from Sigma (St Louis, MO), unless
stated otherwise. Human placenta-derived pericytes (C12980)
were grown in pericyte growth medium (C28040) (PromoCell,
Heidelberg, Germany). The pericytes were subsequently placed
for 18 days in an osteogenic culture medium containing vitamin
D3 (1028 M), dexamethasone (1027 M), ascorbic acid (50 mg/ml)
and b-glycerophosphate (10 mM).
Human bone marrow-derived mesenchymal stem cells (MSC)
from healthy donors [27] were grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal calf serum,
1 ng/mL basic Fibroblast Growth Factor (bFGF; R&D systems),
100 U/ml penicillin, 100 U/ml streptomycin and 2 mM L-
glutamine. Adherent cells were stored frozen at passage two after
characterization by flow cytometry (CD452, CD342, CD105+,
CD73+ and CD90+, purity$99%). MSC were plated at a density
of 104 cells/cm2 in 96-well plates. On day 3 and until day 28,
osteoblastic differentiation was realized and assessed using alizarin
red staining [28].
CD14+ peripheral blood mononuclear cells (PBMC) were
isolated from healthy donors using Ficoll gradient and CD14
microbeads with MACS separators (Miltenyi Biotec, Bergisch
Gladbach, Germany), checked by flow cytometry (CD14+, CD32,
purity$95%), and stored frozen in liquid N2 until use. CD14
+ cells
were grown in 96-well plates (35000 cells/well) using alpha-MEM
(Lonza, Verviers, Belgium) supplemented with 10% FCS and
25 ng/mL of recombinant macrophage colony stimulating factor
(MCSF) (Sigma, St Quentin Fallavier, France). Starting on day 3
and until day 14, the medium was supplemented with RANK-L
(100 ng/mL), with or without 50–100 ng/mL of either recombi-
nant TNFa or IL-6 (R&D Systems) and with 20% of pericyte-
conditioned medium or control medium [28]. On day 14,
multinucleated cells were stained for tartrate-resistant acid
phosphatase (TRAP) using the Leukocyte Acid Phosphatase Assay
kit, and images were analyzed on a D70 camera microscope
(Olympus, Hamburg, Germany).[29] Neutralizing antibody di-
rected against human OPG (TNFRSF11B antibody, R&D
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Systems) was used at a concentration of 0.7 mg/mL, as required by
the instructions provided.
Gene expression
Total RNA was extracted from the pericytes in a subset of wells
using TriZol (Life Technologies, Courtaboeuf, France) and reverse
transcribed. The gene expression levels for osteoblastic markers,
Runt-related transcription factor 2 (RunX2) (F-gtgcctaggcg-
catttca/R-ggctcttcttactgagagtggaag), osteocalcin (F-ggcgctacctgtat-
caatgg/R-tcagccaactcgtcacagtc) and alkaline phosphatase (ALP)
(F-aacaccacccaggggaac/R-ggtcacaatgcccacagatt) were assessed
with real time PCR using SYBR green (Bio-Rad, Marnes la
Coquette, France).
Statistics
Throughout the manuscript, the data are presented as a mean
6 SEM, unless stated otherwise. Statistical analyses were
performed using SSPS 10.0 software. The data were compared
either using the Chi-square test, or the two-sample Student’s t-test,
or a non parametric Mann and Whitney test when appropriate. A
p,0.05 was considered statistically significant.
Results
Osteoid Metaplasia is a specific feature of asymptomatic
carotid plaques
Out of the 73 carotid plaques, OM (=bone-tissue) was noted in
18.4% (9/49) of the asymptomatic and in none (0/24, 0%) of the
symptomatic carotid lesions (p = 0.02) (Fig. 1A and Table 1).
Analysis of imaging data showed that 62.5% of asymptomatic
carotid plaques were highly or moderately calcified vs 8.4% of the
symptomatic lesions (p,0.001) (Table 2).
Osteoid Metaplasia is more frequent in histologically-
assessed stable carotid plaques
Osteoid metaplasia was only observed in asymptomatic lesions.
Vulnerability status of the plaques was determined based on the
modified AHA classification [20]. Symptomatic lesions had
histological signs of vulnerability in 91.7% (22/24) of the cases.
Asymptomatic lesions had no histological sign of vulnerability in
88.1% (37/42) of the cases. Consistently, OM was observed in
only 7.4% (2/27) of the vulnerable plaques and in 17.9% (7/39) of
the non-vulnerable plaques (p = 0.220).
Circulating OPG levels correlate positively with the
asymptomatic nature of carotid plaques, the presence of
OM and histologically-assessed plaque stability
The demographic and cardiovascular characteristics of the
patients were compared. (Table S1 in File S1). Patients with
asymptomatic carotid plaques had higher levels of LDL cholesterol
(0.960.3 g/L vs 0.760.3 g/L, p= 0.02) and presented more
frequently with associated peripheral arterial disease (PAD) (39%
vs 19%, p= 0.05). Patients with symptomatic carotids were more
frequently under 2 antiplatelet agent (50% vs 27%, p= 0.05).
Levels of circulating OPG were found to be significantly higher in
the plasma of patients presenting with asymptomatic carotid
lesions compared to symptomatic carotid lesions (3.261.5 ng/mL
vs 2.561.6 ng/mL, p= 0.05) (Fig. 1B and Table 1). Likewise,
patients with OM in their plaques had significantly more OPG in
their plasma compared to patients without (3.561.2 ng/mL vs
2.361.3 ng/mL, p= 0.03) (Fig. 1B). Finally and consistently,
OPG levels were higher in the plasma of patients presenting with
stable plaques compared to patients presenting with histological
signs of plaque vulnerability (3.4260.22 ng/mL vs 2.6660.28 ng/
mL, p= 0.03) (Fig. 1B).
Cellular OPG expression is higher in asymptomatic
carotid plaques
In line with the plasmatic findings, asymptomatic carotid lesions
contained significantly more OPG than symptomatic carotid
lesions (10.366.6 vs 3.464.5, % area staining, ROI p,0.001)
(Fig. 2A and Table 1).
Intense vascular pericyte presence accompanies calcified
asymptomatic carotid lesions
As we hypothesized that pericytes could be involved in the onset
of mineralized structure in these plaques and in the secretion of
OPG, pericyte presence in the plaques was assessed. Importance of
CD146+ pericyte staining was significantly higher in the asymp-
tomatic carotid lesions compared to the symptomatic carotid
lesions (6.465.0 vs 2.362.8, % area staining, ROI, p,0.001)
(Fig. 2B and Table 1). A subset of sections were stained for NG2
pericyte marker, confirming the results obtained with CD146
(Fig. 3).
A difference towards more CD31+ endothelial staining in
asymptomatic lesions was noted but without reaching statistical
significance (2.364.1 vs 1.261.4% area staining, ROI, p = 0.230
(Fig. 3C and Table 1). Finally, analysis of smooth muscle actin
staining showed no significant difference between the asymptom-
atic and symptomatic carotid lesions (Figure S1 in File S1).
Human pericytes are able to differentiate into osteoblast-
like cells and to mineralize in vitro
To further investigate if pericytes could be responsible for the
intense mineralization and OPG secretion observed in asymp-
tomatic carotid lesions, human primary pericytes (CD312,
CD146+ and NG2+, Figure S2 in File S1) were studied in vitro.
Primary pericytes were able to mineralize when grown in
osteogenic media (Fig. 4A). Simultaneously, PCR analysis showed
that the expression of the osteoblastic differentiation markers
alkaline phosphatase, RunX2, and osteocalcin were significantly
increased (ALP: 17.6-fold, p,0.0001, RunX2: 9.1-fold, p,
0.0001, osteoclacin: 12.2-fold, p,0.0001) (Fig. 4B). At baseline,
human pericytes secreted elevated amount of OPG in comparison
to smooth muscle cells and endothelial cells (Figure S3 in File S1).
Pericyte-derived OPG secretion was significantly increased during
their osteoblastic differentiation as well as under inflammatory
stimulation (Fig. 4C).
Pericytes inhibit the RANKL-dependent differentiation of
pre-osteoclasts into mature osteoclasts through
expression of OPG
Macrophages, abundantly present in the atherosclerotic plaques
represent a potential source of osteoclast-like cells in atheromatous
calcified plaques. To understand the influence of pericytes on the
mineralization balance within the plaque, we tested the effect of
pericyte-conditioned medium on osteoclastogenesis. Pericytes were
cultured under osteoblastic conditions. After 16 to 18 days, we
added fresh FCS-deprived culture medium for an additional 48
hours before collecting the supernatant. We observed that this
osteoblastic pericyte-conditionned medium inhibited the RANKL-
dependent differentiation of PBMC into osteoclasts, as shown by
the significant reduction of TRAP-positive multinucleated cells
in vitro (Fig. 4D). This phenomenon was still observed when
inflammatory-conditionned pericyte supernatants (TNFa or IL6-
pericyte-conditionned medium) were used (Fig. 4D). Since peri-
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cytes secreted increasing amounts of OPG when cultured in
osteogenic medium as well as under TNFa and IL-6 stimulation
(Fig. 4C), we tested the effect of a neutralizing monoclonal
antibody directed against OPG and observed a significant
reversion of this inhibiting effect (Fig. 4E).
Discussion
OPG is a promising predicitive marker for carotid plaque
stability
The main finding of this study is the significant difference in
terms of OPG profile, both plasmatic and intraplaque, between
asymptomatic and symptomatic carotid plaques. Both OPG
presence in the plaque and circulating OPG levels were found
to be significantly higher in the asymptomatic compared to the
symptomatic carotid lesions. OPG is an ubiquitous molecule,
secreted by cells of the cardiovascular system (endothelial cells,
smooth muscle cells, pericytes) but also by other tissues such as
bone and the immune sytem [11,30,31]. The circulating levels of
OPG thus result from the activity of these various organs.
However, here we observed that circulating OPG levels strictly
mirrored intraplaque OPG presence and correlated positively with
carotid plaque stability, suggesting that OPG plasmatic levels
reflect the vulnerability of the carotid lesions. In contrast, imaging
modalities could not accurately distinguish the symptomatic/
vulnerable plaques from the asymptomatic/more stable plaques,
confirming that no robust imaging markers for plaque vulnerabil-
ity are currently available. As a result, plasmatic OPG should be
seriously considered as an interesting potential marker for carotid
plaque stability.
Osteoid Metaplasia is a critical feature of asymptomatic
carotid lesions
The calcic composition of the plaque has a considerable impact
on its clinical behavior (thrombosis, dissection, embolism) or on its
clinical response to treatment (stent fracture, in-stent restenosis). A
significant difference in terms of vascular calcification was
observed between asymptomatic and symptomatic carotid
plaques. Histological analyses and imaging findings showed that
asymptomatic carotid lesions were significantly more calcified than
symptomatic carotid lesions. Interestingly, the main difference in
terms of calcic pattern concerned OM, a highly-evolved bone-like
type of vascular calcification, since almost 20% of the asymptom-
atic (versus none of the symptomatic) displayed OM. In a previous
Figure 1. (A) Representative sections of asymptomatic carotid plaque (left panel) with higher magnification showing dense lamelar structure (*),
osteocytes (arrow), and even bone marrow (arrowhead) typical of osteoid metaplasia (right panel), Masson’s Trichrome staining. (B) Patients
presenting with asymptomatic plaques (AsC) had significantly higher OPG plasmatic levels than symptomatic patients (SC) (left panel). Similar result
was observed when comparing OM+ and OM– groups (middle panel), and histologically-assessed vulnerable and non-vulnerable plaques (right
panel), using Elisa assays.
doi:10.1371/journal.pone.0107642.g001
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work, Hunt et al. made similar observation, showing that highy-
calcified carotid lesions were less prone to induce stroke [3].
Notably, they found a similar (13%) rate of bone formation in the
most calcified lesions. Recent works have established the
importance of microcalcifications in plaque stability [32,33],
strongly suggesting that the presence of microcalcifications in the
thin fibrous cap covering atherosclerotic lesions increase the risk of
rupture. This is consistent with the present results: microcalcifi-
cation may destabilize the lesions by introducing a mismatch at the
interface between soft and hard calcified tissue, while highly-
evolved large calcification could ultimately stabilize the lesion.
Consequently, OM should not only be considered as a marker for
highly-evolved lesions, but also as a qualitative and informative
marker for plaque vulnerability.
Development of OM in the plaques: the more OPG, the
more bone?
The exact influence of OPG remains subject to controversy.
The phenotype of OPG2/2 mice suggests a protective role
against vascular calcification development [34]. In contrast, OPG
levels in humans correlate positively with the calcic burden of the
Table 1. Comparison between asymptomatic and symptomatic carotid groups showed completely diffferent calcic, OPG and
CD146+ cells patterns.
Carotids SC AsC p-value
OM+, n (%) 0 (0%) 9 (18%) 0.02
OM2, n (%) 24 (100%) 40 (82%)
Circulating OPG (ng/ml) 0.05
n 24 49
mean6SD 2.561.6 3.261.5
Intraplaque OPG (% ROI) ,0.001
n 23 39
mean6SD 3.464.5 10.366.6
Intraplaque CD146 (% ROI) ,0.001
n 23 47
mean6SD 2.362.8 6.465.0
Intraplaque CD31(% ROI) 0.230
n 23 46
mean6SD 1.261.4 2.364.1
OM+: presence of osteoid metaplasia, OM2: absence of osteoid metaplasia.
doi:10.1371/journal.pone.0107642.t001
Table 2. Characteristics of the lesions, clinical symptoms and imaging modalities.
SC (24/24) AsC (n=32/49) p-value
Degree of stenosis 0.04
60–69, n(%) 2 (8.3%) 0 (0%)
70–79, n(%) 8 (33.3%) 20 (62.5%)
.80, n(%) 14 (58.3%) 12 (37.5%)
TIA, n(%) 8 (33.3%) - -
Stroke, n(%) 15 (62.5%) - -
Preoperative imaging modalities
Doppler US, n(%) 24 (100%) 32 (100%) -
MRI, n(%) 13 (54.2%) 26 (81.3%) 0.06
CT-scan, n(%) 23(95.8%) 8 (25%) ,0.001
Calcification 0.001
Highly calcified, n(%) 1 (4.2%) 1 (3.1%)
Moderate, n(%) 1 (4.2%) 19 (59.4%)
Mild or none, n(%) 8 (37.4%) 6 (18.8%)
NA, n(%) 13 (54.2%) 7 (18.7%)
Degree of stenosis are reported according to NASCET criteria. Symptomatology is reported as transient ischemic attack (TIA) or stroke. Previous to surgery patients
underwent Doppler-ultrasound (Doppler-us) in all cases and another imaging modality that was whether Magnetic Resonance Imaging (MRI) or Computerized
Tomography Scanner (CT-scan).
doi:10.1371/journal.pone.0107642.t002
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plaque and the severity of the cardiovascular disease [15,16]. In
bone tissue, OPG is secreted by osteoblasts and acts as a soluble
decoy receptor for RANK-Ligand. As a result, osteoclast
differentiation and activation and finally bone resorption are
inhibited. Here, we consistently observed that asymptomatic
carotid lesions, displaying OM, had the highest intraplaque
OPG level. This high mineral presence within the plaque may
ultimately result in a more stable phenotype. Taken together, these
results suggest that an intense secretion of OPG in carotid plaques
promotes the development of OM, which in turn stabilizes the
lesion, leading to the asymptomatic phenotype.
Previous works have shown different results [18,35]. Straface et
al. suggested that high serum OPG levels might be associated with
plaque instability, however, if the plaques were histologically-
assessed regarding their vulnerability status, no information on the
clinical symptoms of the patients were provided, limiting the
clinical relevance of their conclusions. Similarly, Golledge et al.
also observed elevated OPG levels in symptomatic carotid lesions,
but no histological data regarding plaque vulnerability were
provided. In contrast, we here provide both clinical and
histological data of the carotid lesions as well as detailed imaging
data analysis. The results consistently and strongly indicate that
Figure 2. Immunohistochemistry experiments were used to compare symptomatic carotid plaques (SC) and asymptomatic carotid
plaques (AsC). Asymptomatic lesions presented higher OPG infltration, p,0.001 (A), higher CD146+ pericyte infiltration, p,0.001 (B), and higher
CD31+ endothelial cell infiltration, p = 0.23 (C). Representative images are on the left with corresponding quantification on the right.
doi:10.1371/journal.pone.0107642.g002
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higher OPG plasma levels are to be found in patients with
asymptomatic carotid lesions.
Implication of pericytes in the differential regulation of
bone-like vascular calcification
It is now established that bone formation and arterial
calcification share many similarities. In bone, OPG is secreted
by osteoblasts and acts as a decoy receptor for RANKL.
Osteoprotegerin prevents RANKL fixation on its receptor RANK
at the surface of osteoclasts, resulting in the inhibition of osteoclast
proliferation and differentiation. This process finely tunes bone
formation and resorption [36]. In the arterial wall, osteoblast
precursors and the OPG/RANKL/RANK axis have clearly been
identified [13]. During arterial calcification formation, cells with
osteochondrogenic potential differentiate along the osteoblastic
lineage, yet the exact nature of these cells (smooth muscle cells,
endothelial cell, calcifying vascular cells, pericytes) remains to be
elucidated [37]. Vascular smooth muscle cells represent the most
common cell type studied. They have been shown to have
important phenotypic plasticity and when exposed to hydroxyap-
atite cristals, high concentrations of phosphate or inflammatory
cytokines, vascular smooth muscle cells differentiate into osteo-
blastic cells [38]. However, other cells including pericytes have
also been previously shown to be involved in the vascular
calcification process [8,9] and their potential as mesenchymal
precursors has recently been highlighted [39]. Our immuno-
histological results showed no difference in terms of smooth muscle
cells and endothelial cells presence between symptomatic and
asymptomatic plaques. In contrast, higher pericyte cell density was
noted in asymptomatic lesions, suggesting that pericytes could be
actively involved in plaque stability.
The most studied potential sources of OPG in the artery wall
are endothelial cells and smooth muscle cells. Upon inflammatory
Figure 3. NG2 staining was performed on a subset of lesions.
The findings were similar to those obtained with CD146: NG2 pericytes
were found in a higher proportion in the asymptomatic (AsC) carotid
lesions (right panel) than in the symptomatic (SC) carotid lesions (left
panel).
doi:10.1371/journal.pone.0107642.g003
Figure 4. (A) Human primary pericytes underwent osteoblastic differentiation when cultured in an osteogenic media, as shown by Alizarin red
staining. Representative images are above corresponding bars. (B) PCR experiments confirmed that during this process, pericytes increasingly
expressed the ALP (p,0.0001), Runx2 (p,0.0001) and osteocalcin (Oc) (p,0.0001) characteristic markers of osteoblasts. (C) CD14+ cells were cultured
during 14 days with standard media (CT2) or with addition of M-CSF and RANKL (CT+), after which TRAP staining was realized and giant
multinucleated cells counted. Addition of pericytes supernatant (PSN) to the medium (in the proportion of 10% and 20%) dose-dependently inhibited
the osteoclastic differentiation. A similar result was obtained when IL-6 and TNF-a pericyte-conditioned supernatant were used. Representative
images are displayed above the bars. (D) Elisa experiments showed that pericytes expressed increasing amounts of OPG along their osteoblastic
differentiation (upper graph) but also under inflammatory stimulation by IL-6 and TNF-a (lower graph). (E) CD14+ cells were cultured to undergo
osteoclastic differentiation as in (C). Addition of OPG (25 ng/ml and 100 ng/ml), inhibited the formation of multinucleated cells. Addtion of PSN
produced similar effect. Finally, addition of an antibody directed against OPG (PSN + anti-OPG) significantly reversed this inhibition. All experiments
were realized three times in triplicate. CT-: media with RANKL, CT+: media with RANKL and MCSF.
doi:10.1371/journal.pone.0107642.g004
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stimulation, these cells release OPG in the surrounding extra-
cellular matrix as well as in the circulation, which is one of the
possible sources of circulating OPG in atherosclerotic patients
[40]. Based on in vitro preliminary results, we observed that
unstimulated pericytes had an intense secretion of OPG at baseline
in comparison to smooth muscle cells and endothelial cells (Figure
S3 in File S1). Altogether, these notions led us to hypothesize that
vascular pericytes could play a critical role in arterial calcification
formation and regulation, similar to that of osteoblasts in bone
tissue. To confirm this hypothesis, we first assessed the presence of
pericytes in our cohort of carotid plaques. We observed CD146+
and NG2+ pericyte cell presence in the lesions but with a
significantly more intense staining in the asymptomatic carotid
plaques. Of note, no significant difference was noted in terms of
CD31+ endothelial staining nor in terms of actin staining, further
suggesting that pericytes could be responsible for this difference
(Fig. 2). Then, we assessed the osteoblastic potential of human
primary pericytes in vitro. We showed that human pericytes were
able to differentiate into osteoblast-like cells and to mineralize
(Fig. 4A and 4B). Finally, we found that pericytes secreted
increasing amounts of OPG during osteoblastic differentiation
and upon inflammatory stimulation by IL-6 and TNF-a (Fig. 4D).
In other words, pericytes, that have the ability to differentiate into
osteoblasts and to secrete high amounts of OPG were found in a
significantly higher proportion in the asymptomatic plaques that
were precisely characterized by an intense presence of both
pericyte cells, OPG, as well as a higher proportion of osteoid
metaplasia.
As in bone tissue, it is hypothesized that in ectopic calcification,
mineral deposition and resorption are two opposite processes
tightly balanced and regulated by osteoblast- and osteoclast-like
cells. Cells from the monocytic lineage are most likely the
precursors of the giant multinucleated cells observed in athero-
sclerosis lesions [10]. Following on with this hypothesis, we
observed that pericytes supernatant inhibited the differentiation of
Hu- CD14+ cells into osteoclasts, an effect that persisted under IL-
6 and TNF-a inflammatory stimulation (Fig. 4C). Given the
intense secretion of OPG by pericytes during osteoblastic
differentiation and under inflammatory stimulation (Fig. 4D), we
hypothesized that this inhibitory effect was OPG-mediated.
Indeed, blockage of OPG using a neutralizing antibody proved
efficient in significantly reversing this inhibition (Fig. 4E).
Altogether, these results suggest that pericytes are implicated in
the formation of vascular calcification. Resident vascular pericytes
may have a protective effect against the development of vascular
calcification by regulating the balance of mineral formation
together with other cells such as monocytes/macrophages.
Exposure to inflammatory atherosclerotic stress induces pericytes
to (i) differentiate towards an osteoblastic lineage and (ii) secrete
various mediators, including OPG, which trigger an imbalance
between mineral formation and resorption in the plaque. As a
result, intense calcification, and in some cases OM, develop within
atherosclerotic lesions which ultimately may stabilize the plaque.
Study limitations and perpesctives
Our results suggest that OPG is an interesting predicitive
marker for carotid plaque vulnerability in patients presenting with
carotid artery stenosis, however the plasma evaluation is based on
a the analysis of a single blood sample harvested the day before
surgery. A clinical study comprising serial plasmatic OPG
evaluations of symptomatic and asymptomatic patients is war-
ranted to confirm the relevance of OPG as a predictive factor for
carotid plaque stability in routine clinical practice.
The intense expression of OPG in asymptomatic carotid lesions
is associated with the presence of OM. Whether OPG is secreted
in response to atherosclerosis-related stress and fosters the
development of bone-like vascular calcification or is secreted as
a retaliatory metabolite that is finally overwhelmed is not clear and
further studies are needed to address this aspect.
Finally, the presence of OM seems to be noted consistently and
exclusively in the asymptomatic lesions, making OM an interesting
qualitative marker for plaque composition. However, to our
knowledge, no imaging modality can distinguish OM from other
types of vascular calcification.
Conclusion
Our study shows that asymptomatic and symptomatic carotid
lesions are completely opposed in terms of OPG and calcic
patterns. Asymptomatic plaques are characterized by an intense
mineralization with often the presence of OM, a high OPG and
pericytes presence as well as elevated circulating OPG levels.
These completely different profiles suggest that circulating OPG
could be a useful plasmatic predictive factor for plaque vulnera-
bility in clinical practice. Furthermore, our studies indicate that
OPG and pericytes are governing factors in the develoment of
arterial calcification.
Supporting Information
File S1 File S1 contains Table S1 and Figures S1, S2 and
S3.
(DOCX)
Acknowledgments
We thank Carine Montagne and Annie Guillard for the management of
the biocollection.
Author Contributions
Conceived and designed the experiments: JMD DH YG MFH. Performed
the experiments: JMD RB OL TMMC FGMAB CCMFH TQ. Analyzed
the data: JMD BG YG DH MFH TQ. Contributed reagents/materials/
analysis tools: JMD DH YG MFH. Contributed to the writing of the
manuscript: JMD YG DH MFH.
References
1. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW,
et al. (2009) Vascular calcifications as a marker of increased cardiovascular risk:
a meta-analysis. Vasc Health Risk Manag 5: 185–197.
2. Hoshino T, Chow LA, Hsu JJ, Perlowski AA, Abedin M, et al. (2009)
Mechanical stress analysis of a rigid inclusion in distensible material: a model of
atherosclerotic calcification and plaque vulnerability. Am J Physiol Heart Circ
Physiol 297: H802–810.
3. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, et al. (2002) Bone
formation in carotid plaques: a clinicopathological study. Stroke 33: 1214–1219.
4. Qiao JH, Mertens RB, Fishbein MC, Geller SA (2003) Cartilaginous metaplasia
in calcified diabetic peripheral vascular disease: morphologic evidence of
enchondral ossification. Hum Pathol 34: 402–407.
5. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, et al. (2009) RANKL
increases vascular smooth muscle cell calcification through a RANK-BMP4-
dependent pathway. Circ Res 104: 1041–1048.
6. Bunting CH (1906) The Formation of True Bone with Cellular (Red) Marrow in
a Sclerotic Aorta. J Exp Med 8: 365–376.
7. Andreeva ER, Pugach IM, Gordon D, Orekhov AN (1998) Continuous
subendothelial network formed by pericyte-like cells in human vascular bed.
Tissue Cell 30: 127–135.
Osteoprotegerin and OM Influence Carotid Plaque Stability
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107642
8. Collett GD, Canfield AE (2005) Angiogenesis and pericytes in the initiation of
ectopic calcification. Circ Res 96: 930–938.
9. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, et al. (1993) Bone
morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest
91: 1800–1809.
10. Oksala N, Levula M, Pelto-Huikko M, Kytomaki L, Soini JT, et al. (2010)
Carbonic anhydrases II and XII are up-regulated in osteoclast-like cells in
advanced human atherosclerotic plaques-Tampere Vascular Study. Ann Med
42: 360–370.
11. Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast
regulatory factors RANKL and osteoprotegerin. Circ Res 95: 1046–1057.
12. Wong KK, Thavornpattanapong P, Cheung SC, Sun Z, Tu J (2012) Effect of
calcification on the mechanical stability of plaque based on a three-dimensional
carotid bifurcation model. BMC Cardiovasc Disord 12: 7.
13. Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, et al. (2012)
Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous
plaques: comparison between carotid and femoral beds. Cytokine 58: 300–306.
14. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, et al. (2012)
Osteoprotegerin/RANKL axis and progression of coronary artery calcification
in hemodialysis patients. Clin J Am Soc Nephrol 7: 965–973.
15. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, et al. (2007) Relation of
osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart
Study). Am J Cardiol 99: 513–518.
16. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, et al. (2008)
Circulating osteoprotegerin levels and long-term prognosis in patients with acute
coronary syndromes. J Am Coll Cardiol 51: 627–633.
17. Ziegler S, Kudlacek S, Luger A, Minar E (2005) Osteoprotegerin plasma
concentrations correlate with severity of peripheral artery disease. Atheroscle-
rosis 182: 175–180.
18. Golledge J, McCann M, Mangan S, Lam A, Karan M (2004) Osteoprotegerin
and osteopontin are expressed at high concentrations within symptomatic
carotid atherosclerosis. Stroke 35: 1636–1641.
19. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, et
al. (2008) The relationship between serum levels of vascular calcification
inhibitors and carotid plaque vulnerability. J Vasc Surg 47: 55–62.
20. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, et al. (1995) A
definition of advanced types of atherosclerotic lesions and a histological
classification of atherosclerosis. A report from the Committee on Vascular
Lesions of the Council on Arteriosclerosis, American Heart Association.
Circulation 92: 1355–1374.
21. (1998) Randomised trial of endarterectomy for recently symptomatic carotid
stenosis: final results of the MRC European Carotid Surgery Trial (ECST).
Lancet 351: 1379–1387.
22. (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with
high-grade carotid stenosis. N Engl J Med 325: 445–453.
23. Rerkasem K, Rothwell PM (2009) Systematic review of the operative risks of
carotid endarterectomy for recently symptomatic stenosis in relation to the
timing of surgery. Stroke 40: e564–572.
24. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, et al. (2003)
Analysis of pooled data from the randomised controlled trials of endarterectomy
for symptomatic carotid stenosis. Lancet 361: 107–116.
25. (1995) Endarterectomy for asymptomatic carotid artery stenosis. Executive
Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273:
1421–1428.
26. Herisson F, Heymann MF, Chetiveaux M, Charrier C, Battaglia S, et al. (2011)
Carotid and femoral atherosclerotic plaques show different morphology.
Atherosclerosis 216: 348–354.
27. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, et al. (2010) Clinical-
grade production of human mesenchymal stromal cells: occurrence of
aneuploidy without transformation. Blood 115: 1549–1553.
28. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, et al. (2004)
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate
aortic valve calcification. J Mol Cell Cardiol 36: 57–66.
29. Duplomb L, Baud’huin M, Charrier C, Berreur M, Trichet V, et al. (2008)
Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced
osteoclastogenesis by diverting cells into the macrophage lineage: key role of
Serine 727 phosphorylation of signal transducer and activator of transcription 3.
Endocrinology 149: 3688–3697.
30. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997)
Osteoprotegerin: a novel secreted protein involved in the regulation of bone
density. Cell 89: 309–319.
31. Wong BR, Josien R, Lee SY, Sauter B, Li HL, et al. (1997) TRANCE (tumor
necrosis factor [TNF]-related activation-induced cytokine), a new TNF family
member predominantly expressed in T cells, is a dendritic cell-specific survival
factor. J Exp Med 186: 2075–2080.
32. Maldonado N, Kelly-Arnold A, Vengrenyuk Y, Laudier D, Fallon JT, et al.
(2012) A mechanistic analysis of the role of microcalcifications in atherosclerotic
plaque stability: potential implications for plaque rupture. Am J Physiol Heart
Circ Physiol 303: H619–628.
33. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, et al. (2013)
Macrophage-derived matrix vesicles: an alternative novel mechanism for
microcalcification in atherosclerotic plaques. Circ Res 113: 72–77.
34. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998)
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial
calcification. Genes Dev 12: 1260–1268.
35. Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, et al. (2011)
Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene,
TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability.
Stroke 42: 3022–3028.
36. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998)
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and
activation. Cell 93: 165–176.
37. Tang Z, Wang A, Yuan F, Yan Z, Liu B, et al. (2012) Differentiation of
multipotent vascular stem cells contributes to vascular diseases. Nat Commun 3:
875.
38. Tintut Y, Patel J, Parhami F, Demer LL (2000) Tumor necrosis factor-alpha
promotes in vitro calcification of vascular cells via the cAMP pathway.
Circulation 102: 2636–2642.
39. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr., Orellana MD, et al. (2008)
Multipotent mesenchymal stromal cells obtained from diverse human tissues
share functional properties and gene-expression profile with CD146+ perivas-
cular cells and fibroblasts. Exp Hematol 36: 642–654.
40. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, et al. (2005)
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human
vascular endothelial cells and is physically associated with von Willebrand factor.
J Cell Physiol 204: 714–723.
Osteoprotegerin and OM Influence Carotid Plaque Stability
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107642
